Brinzolamide/Brimonidine Tartrate

布林佐胺/酒石酸溴莫尼定

Report date: 2023/09/15 15:13:55

Base Information

Drug NameBrinzolamide/Brimonidine Tartrate
Drug Alias NameBrinzolamide/Brimonidine布林佐胺酒石酸溴莫尼定酒石酸溴莫尼定布林佐胺Brimonidine Tartrate/BrinzolamideBrinzolamide and Brimonidine Tartrate +[8] 
ClassificationSmall molecules
Mechanisms of ActionCarbonic anhydrase II inhibitorsAdrenergic receptors alpha-2 agonists
TargetsAdrenergic receptors alpha-2Carbonic anhydrase II
Therapy Area/IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Global Approved IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Approved Indications in ChinaGlaucoma, Open-AngleOcular Hypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2013/04/19
Country/TerritoryUnited StatesTaiwanRussian Federation +[6] 
CombinationsYes Brimonidine TartrateBrinzolamide
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceutical Co LtdOtsuka Pharmaceutical Co LtdNovartis Europharm Ltd +[5] 
Inactive CompaniesSA Alcon Couvreur NVAlconPadagis LLC +[4] 
Active IndicationsGlaucoma, Open-AngleGlaucomaOcular Hypertension
Inactive IndicationsN/A

Other Information

ATC CodeS01EC54
Related LinksKEGG